A06431 Summary:

BILL NOA06431
 
SAME ASSAME AS S05604
 
SPONSORHyndman
 
COSPNSRGalef, Dickens, Perry, Anderson, Paulin, Simon, Steck, McDonald
 
MLTSPNSR
 
Add §2807-aa, amd §3331, Pub Health L
 
Establishes the "Sickle Cell Treatment Act" which designates sickle cell centers for excellence and outpatient treatment centers.
Go to top    

A06431 Actions:

BILL NOA06431
 
03/17/2021referred to health
04/19/2021reported referred to ways and means
01/05/2022referred to ways and means
Go to top

A06431 Committee Votes:

HEALTH Chair:Gottfried DATE:04/19/2021AYE/NAY:26/0 Action: Favorable refer to committee Ways and Means
GottfriedAyeByrneAye
GalefAyeMcDonoughAye
DinowitzAyeByrnesAye
CahillAyeAshbyAye
PaulinAyeMillerAye
CymbrowitzAyeSalkaAye
GuntherAyeJensenAye
Rosenthal L Aye
HevesiAye
SteckAye
AbinantiAye
BraunsteinAye
SolagesAye
BichotteAye
BarronAye
SayeghAye
Rosenthal D Aye
McDonaldAye
ReyesAye

Go to top

A06431 Floor Votes:

There are no votes for this bill in this legislative session.
Go to top

A06431 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
submitted in accordance with Assembly Rule III, Sec 1(f)
 
BILL NUMBER: A6431
 
SPONSOR: Hyndman
  TITLE OF BILL: An act to amend the public health law, in relation to establishing the "Sickle Cell Treatment Act"; and making an appropriation therefor   PURPOSE: Establishes the Sickle Cell Treatment Act   SUMMARY OF SPECIFIC PROVISIONS: Section 1 of the bill would set forth that this act shall be known and may be cited as the "Sickle Cell Treatment Act". Section 2 amends the public health law by adding a new section 2807-aa which mandates the Commissioner of the Department of Health to designate Sickle cell centers for excellence and outpatient treatment centers. Section 3 amends subdivision 8 of section 3331 of the public health law, as added by section 7-a of part D of chapter 57 of the laws of 2018 relating to opioid exemption. Section 4 provides the effective date.   JUSTIFICATION: Sickle Cell patients experience a multitude of symptoms that can range from mild to severe. There is little to no awareness of possible ways to manage these symptoms, which is why centers for excellence (COE), and outpatient treatment centers are essential. The Centers of Excellence would serve as a hub for adults and children alike to have access to professionals that can understand, monitor, and provide care in the most effective way possible. The COEs would further serve as leaders to other institutions in the treatment of SCD and would establish the best practices that could then be used in other healthcare facilities around the state. Outpatient hospitals would help reduce the need of sickle cell patients to check into the emergency room for pain, which is the traditional response of people who are suffering an SCD pain crisis. Patients would have access to readily available services that are designated to help specifically with SCD pain management and symptoms because outpatient services would be available in areas where there is sufficient need for the service. The reduced burden on emergency rooms, especially in times of health crisis, can help patients and doctors alike. Pain is a major symptom of Sickle Cell disease (SCD) and one of the principal reasons that people with SCD go to the emergency room. Pain experienced by sickle cell patients manifests itself as abrupt and very debilitating pain in any part of the body. Individuals diagnosed with sickle cell can begin having pain crises as early as 6 months of age. This legislation will allow certain sickle cell patients to easily gain access to opioid therapy. Currently, sickle cell patients are restricted in being treated with opioids. However, due to the debilitating pain sickle cell disease patients encounter during crisis, opioid therapy serves to reduce the pain that patients experience.   FISCAL IMPLICATIONS: To be determined   EFFECTIVE DATE: This act shall take effect immediately.
Go to top

A06431 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          6431
 
                               2021-2022 Regular Sessions
 
                   IN ASSEMBLY
 
                                     March 17, 2021
                                       ___________
 
        Introduced  by M. of A. HYNDMAN -- read once and referred to the Commit-
          tee on Health
 
        AN ACT to amend the public health law, in relation to  establishing  the
          "Sickle Cell Treatment Act"; and making an appropriation therefor
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:

     1    Section 1. This act shall be known and may be  cited  as  the  "Sickle
     2  Cell Treatment Act".
     3    §  2. The public health law is amended by adding a new section 2807-aa
     4  to read as follows:
     5    § 2807-aa. Sickle cell centers for excellence and outpatient treatment
     6  centers. 1. Centers for sickle cell care  excellence.  The  commissioner
     7  shall  designate  five general hospitals or hospices under article forty
     8  of this chapter, upon successful application, as centers for sickle cell
     9  care excellence. The designations shall be made through  an  application
    10  designed  by  the  department,  and based on service, staffing and other
    11  criteria as developed by the commissioner.  The  centers  of  excellence
    12  shall  provide  specialized sickle cell disease care, treatment, pallia-
    13  tive care, education and related services and shall conduct  specialized
    14  research into the care, treatment and management of sickle cell disease.
    15  Designation  as a center for sickle cell care excellence shall not enti-
    16  tle a center to enhanced reimbursement, but may be utilized in  outreach
    17  and  other  promotional  activities.  Each  center  for sickle cell care
    18  excellence shall affiliate and cooperate with major  centers  of  higher
    19  learning,  including  medical colleges, and life science research insti-
    20  tutes in the state.  The state university shall enter  into  appropriate
    21  legal agreements to enable this cooperation. Each center for sickle cell
    22  care excellence shall receive two hundred thousand dollars per year from
    23  the  department,  from amounts appropriated for that purpose, to be used
    24  on sickle cell disease research.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD08525-01-1

        A. 6431                             2
 
     1    2. Outpatient treatment centers. The commissioner shall designate  ten
     2  hospitals,  distributed  based on sickle cell patient population concen-
     3  trations, as  sickle  cell  outpatient  treatment  centers  which  shall
     4  provide  patients  treatment  for  sickle cell disease as an outpatient.
     5  Each  sickle  cell outpatient treatment center shall receive one hundred
     6  thousand dollars per year from the department, from amounts appropriated
     7  for that purpose, to be used to ensure the proper management and  equip-
     8  ping of the centers to care for sickle cell patients.
     9    §  3. Subdivision 8 of section 3331 of the public health law, as added
    10  by section 7-a of part D of chapter 57 of the laws of 2018,  is  amended
    11  to read as follows:
    12    8.  No  opioids  shall  be prescribed to a patient initiating or being
    13  maintained on opioid treatment for pain which has lasted more than three
    14  months or past the time of normal tissue  healing,  unless  the  medical
    15  record contains a written treatment plan that follows generally accepted
    16  national  professional  or  governmental guidelines. The requirements of
    17  this paragraph shall not apply in the case of  patients  who  are  being
    18  treated  for cancer or sickle cell disease that is not in remission, who
    19  are in hospice or other end-of-life care, or whose pain is being treated
    20  as part of palliative care practices.
    21    § 4. This act shall take effect immediately.
Go to top